We are live on ! Find out more
CC

Callan Capital Portfolio holdings

AUM $1.35B
1-Year Est. Return 8.35%
This Fund
S&P 500
This Quarter Est. Return
+6.01%
1 Year Est. Return
+8.35%
3 Year Est. Return
+20.11%
5 Year Est. Return
+98.58%
10 Year Est. Return
+95.87%
AUM
$243M
AUM Growth
-$2.1M
Cap. Flow
-$15.4M
Cap. Flow %
-6.33%
Top 10 Hldgs %
78.49%
Holding
71
New
3
Increased
8
Reduced
27
Closed
26

Top Buys

Rank Stock Value
1
VEU icon
Vanguard FTSE All-World ex-US ETF
VEU
+$701K
2
GSLC icon
Goldman Sachs ActiveBeta US Large Cap Equity ETF
GSLC
+$572K
3
ALR
Alere Inc
ALR
+$290K
4
IWB icon
iShares Russell 1000 ETF
IWB
+$251K
5
FNDB icon
Schwab Fundamental US Broad Market Index ETF
FNDB
+$230K

Top Sells

Rank Stock Value
1
IBRX icon
ImmunityBio
IBRX
+$2.66M
2
BDX icon
Becton Dickinson
BDX
+$2.16M
3
ARE icon
Alexandria Real Estate Equities
ARE
+$1.15M
4
RMD icon
ResMed
RMD
+$1.02M
5
BIIB icon
Biogen
BIIB
+$881K

Sector Composition

Rank Sector Weight
1 Miscellaneous 88.95%
2 Healthcare 11.05%
3 Consumer Discretionary 0%
4 Consumer Staples 0%
5 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CDTX
51
DELISTED
Cidara Therapeutics
CDTX
– –
-593
Closed -$122K
EPP icon
52
iShares MSCI Pacific ex Japan ETF
EPP
$2.32B
– –
-6,330
Closed -$248K
ILMN icon
53
Illumina
ILMN
$32.6B
– –
-1,772
Closed -$242K
MINT icon
54
PIMCO Enhanced Short Maturity Active Exchange-Traded Fund
MINT
$17.4B
– –
-3,103
Closed -$314K
NBIX icon
55
Neurocrine Biosciences
NBIX
$15.7B
– –
-15,000
Closed -$682K
PPBI
56
DELISTED
Pacific Premier Bancorp
PPBI
– –
-8,862
Closed -$213K
RMD icon
57
ResMed
RMD
$34.7B
– –
-16,183
Closed -$1.02M
TSLA icon
58
Tesla
TSLA
$1.38T
– –
-19,650
Closed -$278K
CTLT
59
DELISTED
CATALENT, INC.
CTLT
– –
-11,700
Closed -$269K
SEEL
60
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
– –
0
– -$26K
APTO
61
DELISTED
Aptose Biosciences, Inc.
APTO
– –
-27
Closed -$29K
BIOC
62
DELISTED
Biocept, Inc.
BIOC
– –
-1
Closed -$25K
ZVO
63
DELISTED
Zovio Inc. Common Stock
ZVO
– –
-49,036
Closed -$355K
HNGR
64
DELISTED
Hanger Inc.
HNGR
– –
-20,836
Closed -$155K
ARNA
65
DELISTED
Arena Pharmaceuticals Inc
ARNA
– –
-1,200
Closed -$21K
MBFI
66
DELISTED
MB Financial Corp
MBFI
– –
-13,905
Closed -$504K
KND
67
DELISTED
Kindred Healthcare
KND
– –
-39,494
Closed -$446K
MON
68
DELISTED
Monsanto Co
MON
– –
-6,098
Closed -$631K
WMAR
69
DELISTED
West Marine Inc
WMAR
– –
-20,200
Closed -$169K
SQNM
70
DELISTED
SEQUENOM INC NEW
SQNM
– –
-176,777
Closed -$162K
CELG
71
DELISTED
Celgene Corp
CELG
– –
-3,100
Closed -$306K
1 2
3

Similar funds

MBA
Maple-Brown Abbott Barangaroo, Australia $1.47B AUM 27.26% 1-Year Est. Return
SIA
Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.73% 1-Year Est. Return
AP
Adero Partners Pleasanton, California $1.53B AUM 5.52% 1-Year Est. Return
MW
Marcum Wealth Cleveland, Ohio $1.16B AUM 6.7% 1-Year Est. Return
SBIA
Sheaff Brock Investment Advisors Indianapolis, Indiana $1.09B AUM 14.4% 1-Year Est. Return
LC
Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return
TW
Transform Wealth Greenwood Village, Colorado $1.65B AUM 19.1% 1-Year Est. Return
PAME
Parvus Asset Management Europe London, United Kingdom $1.67B AUM

Callan Capital's Q3 2016 Portfolio in Review

As of Q3 2016, Callan Capital held 71 positions worth $243M, down 0.86% from $245M the previous quarter. Its ten largest holdings account for 78% of the portfolio.

Callan Capital withdrew a net $15.4M in Q3 2016, closing 26 positions and reducing 27 holdings. Its most notable exit was Becton Dickinson, an estimated $2.16M position sold in full.

By sector, the portfolio is most concentrated in Miscellaneous at 89% of assets, up from 86% a quarter earlier, followed by Healthcare and Consumer Discretionary.

Against the trend, Callan Capital opened a new position in Alere Inc worth $307K.

  • Callan Capital's largest Q3 2016 buy was Alere Inc: 7,100 shares worth $307K.
  • Callan Capital added most to Vanguard FTSE All-World ex-US ETF in Q3 2016, an estimated $701K increase.
  • Callan Capital's biggest Q3 2016 reduction was ImmunityBio, cutting an estimated $2.66M.
  • Callan Capital fully exited Becton Dickinson in Q3 2016, selling an estimated $2.16M.
  • Callan Capital's ten largest holdings make up 78% of its $243M portfolio in Q3 2016.
  • Callan Capital opened 3 new positions and closed 26 in Q3 2016.
  • Callan Capital's portfolio value fell 0.86% quarter-over-quarter to $243M.

Based on Callan Capital's 13F filing for Q3 2016, filed 15 Nov 2016.